CoChat

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Open access
SVATON, MARTIN, ZEMANOVA, MILADA, ZEMANOVA, PETRA, KULTAN, JURAJ, FISCHER, ONDREJ, SKRICKOVA, JANA, JAKUBIKOVA, LENKA, CERNOVSKA, MARKETA, HRNCIARIK, MICHAL, JIROUSEK, MICHAL, KREJCI, JANA, KREJCI, DANIEL, BILEK, ONDREJ, BLAZEK, JIRI, HURDALKOVA, KAROLINA, BARINOVA, MAGDA, MELICHAR, BOHUSLAV · 2020 · Anticancer Research
Cited by 88

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

AIM: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. RESULTS: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. CONCLUSION: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21873/anticanres.14182

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 88

Metadata

Authors
SVATON, M., ZEMANOVA, M., ZEMANOVA, P., KULTAN, J., FISCHER, O., SKRICKOVA, J., JAKUBIKOVA, L., CERNOVSKA, M., HRNCIARIK, M., JIROUSEK, M., KREJCI, J., KREJCI, D., BILEK, O., BLAZEK, J., HURDALKOVA, K., BARINOVA, M., & MELICHAR, B.
Venue
Anticancer Research
Published
2020-03-31
Volume
40
Issue
4
Pages
2209-2217
ISSN
  • 0250-7005 (ISSN-L)
  • 1791-7530
OpenAlex
W3014912043
Cited by
88
References
13
FWCI
4.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.